Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Fidelity Management & Research Company
Deal Size : $81.0 million
Deal Type : Series B Financing
Details : The financing will be used to advance generative AI-powered drug discovery platform and product development for novel treatments and therapeutic approaches.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Fidelity Management & Research Company
Deal Size : $81.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : $400.0 million
Deal Type : Collaboration
Details : In partnership with Takeda, Evozyne will create novel protein sequences for advancement as gene therapies for up to four rare disease targets using Evozyne’s protein engineering platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 04, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : $400.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Evozyne and Takeda Announce Strategic Collaboration and License Agreement
Details : In partnership with Takeda, Evozyne will create novel protein sequences for advancement as gene therapies. At completion Takeda has the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene the...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 25, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration